VBI Vaccines (VBIV) Receives a Buy from Oppenheimer
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on VBI Vaccines (VBIV), with a price target of $8.00. The company’s shares closed last Thursday at $3.72.
According to TipRanks.com, Gershell is a 3-star analyst with an average return of 2.3% and a 41.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for VBI Vaccines with a $6.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.93 and a one-year low of $0.47. Currently, VBI Vaccines has an average volume of 14.77M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VBI Vaccines, Inc. is a biopharmaceutical company. It engages in the development of eVLP vaccine platform for the design of (e) virus-like-particle vaccines that closely mimic the target virus. The company also involves in the development of thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI Vaccines was founded on July 25, 2014 and is headquartered in Cambridge, MA.
Read More on VBIV: